Ondine Biomedical (OBI) Q4 2024 earnings summary

Executive summary

• 2024 marked a transformative year with robust commercial expansion, significant growth in hospital adoption, and the launch of a pivotal phase three study with HCA Healthcare.

• Strategic distribution partnership with Mölnlycke Health Care to accelerate EMEA, EU, and Middle East market entry.

• Launched a high-volume, high-margin Illuminator System, driving steady revenue growth.

• Successfully raised CAD 21.7 million (or $21.7 million) in 2024, with an additional CAD 5.7 million strategic investment from HCA Healthcare post-year-end.

• US Phase 3 clinical trial for Steriwave underway, supporting regulatory and commercial strategy.

Financial highlights

• Revenue increased by 70% year-over-year to CAD 2 million (or $2.0 million) in 2024, up from CAD 1.2 million in 2023.

• Gross margin improved to 64% from 58% in 2023, driven by operational efficiencies and the new Illuminator.

• Operating/net loss widened to CAD 19.4 million (or $19.1 million) from CAD 14.8 million (or $14.4 million) in 2023, reflecting investments in clinical studies and infrastructure.

• Loss per share remained at $(0.07) CAD.

• Cash reserves at year-end were just under CAD 10 million.

Outlook and guidance

• Cash runway extends into early Q4 2025, with disciplined cost controls and active pursuit of non-dilutive and strategic funding.

• Key priorities for the next 12 months include commercial growth, expanding Steriwave adoption, completing clinical studies, and scaling operational infrastructure.

• Platform positioned for multi-directional growth, targeting $10+ billion annual revenue potential in North America and Europe.

• Plans to launch additional products and expand indications and geographies.